Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00295763 | A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen. | PHASE3 | COMPLETED | 61 | — | — | May 1, 2006 | Sep 1, 2006 | Mar 18, 2015 | 9 | United States, Canada +3 |
| Arm | Type | Description |
|---|---|---|
| 1 | OTHER | - |
| Name | Type | Description |
|---|---|---|
| Thyrogen (thyrotropin alfa for injection) | DRUG | No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days. For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO. |
Inclusion Criteria: * Committed to follow the protocol requirements, as evidenced by providing written informed consent before any study-related procedures are performed and within 28 days prior to Day 1; * Completed the THYR-008-00 study; * A negative serum pregnancy test within 8 days prior to th...